Drug Profile
Sargramostim biosimilar - Sandoz
Latest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Sandoz
- Developer National Institutes of Health (USA); Sandoz
- Class Adjuvants; Anti-infectives; Antidementias; Antineoplastics; Antiparkinsonians; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors; Radioprotectives
- Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Leucopenia
Most Recent Events
- 25 Jul 2016 Discontinued - Clinical-Phase-Unknown for Leucopenia (In children, In infants) in USA (SC)
- 25 Jul 2016 Discontinued - Phase-I/II for Leucopenia in USA (SC, IV)